Officials at Northway Biotech say they will leverage the company’s expertise to develop a robust manufacturing process for KAD101. This involves Northway’s developing and qualifying analytical methods, optimizing the formulation, development and scaling up of the production process, and manufacturing a cGMP drug substance batch for clinical studies.
“We are incredibly pleased to establish this important partnership with Northway Biotech, a pre-eminent CDMO, to manufacture the clinical drug product necessary for our planned Phase 1 clinical study for our lead program, KAD101.
“We believe that the expertise and skill sets provided to Kaida by entering into this strategic partnership represents a significant step forward for the company and our clinical development program,” said Craig Pierson, founder and chairman of Kaida BioPharma. “We look forward to working closely with the Northway Biotech team to advance our lead product candidate, KAD101 and progress towards providing targeted anti-cancer therapies to address hormone-driven cancers affecting women.”
“We are proud to partner with Kaida BioPharma on the development of KAD101,” added Vladas Algirdas Bumelis, PhD, CEO, and Chairman of Northway Biotech.
Kaida is advancing targeted anti-cancer hormonal therapies to address the root cause of cancers affecting women, noted Pierson. Its lead program, KAD101 is a biologic that blocks the prolactin receptor to prevent cancer cell growth signals and incite autophagy initially targeting ovarian cancer. The original biologic G129R, demonstrated encouraging results in a human clinical study with all patients showing tumor reduction on the low dose cohort with a clean safety profile as a daily injectable, noted Pier.
The post Northway Biotech Signs Deal with Kaida BioPharma for Production of Kaida’s Ovarian Cancer Therapeutic appeared first on GEN - Genetic Engineering and Biotechnology News.
“We are incredibly pleased to establish this important partnership with Northway Biotech, a pre-eminent CDMO, to manufacture the clinical drug product necessary for our planned Phase 1 clinical study for our lead program, KAD101.
“We believe that the expertise and skill sets provided to Kaida by entering into this strategic partnership represents a significant step forward for the company and our clinical development program,” said Craig Pierson, founder and chairman of Kaida BioPharma. “We look forward to working closely with the Northway Biotech team to advance our lead product candidate, KAD101 and progress towards providing targeted anti-cancer therapies to address hormone-driven cancers affecting women.”
“We are proud to partner with Kaida BioPharma on the development of KAD101,” added Vladas Algirdas Bumelis, PhD, CEO, and Chairman of Northway Biotech.
Kaida is advancing targeted anti-cancer hormonal therapies to address the root cause of cancers affecting women, noted Pierson. Its lead program, KAD101 is a biologic that blocks the prolactin receptor to prevent cancer cell growth signals and incite autophagy initially targeting ovarian cancer. The original biologic G129R, demonstrated encouraging results in a human clinical study with all patients showing tumor reduction on the low dose cohort with a clean safety profile as a daily injectable, noted Pier.
The post Northway Biotech Signs Deal with Kaida BioPharma for Production of Kaida’s Ovarian Cancer Therapeutic appeared first on GEN - Genetic Engineering and Biotechnology News.